For instance, a phase I/II clinical trial (NCT00022334) conducted by Butterfield et al. evaluated mature DC vaccines pulsed with AFP-derived peptides (AFP137-145, AFP158-166, AFP325-334, AFP542-550) in HLA-A*0201-positive patients with AFP-expressing HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.